Company: SION
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049251
Chunk: 352

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 8
Chunk 352
---
 Ended September 30,Change20252024Operating expenses:Research and development$45,095 $43,035 $2,060 General and administrative20,275 9,388 10,887 Total operating expenses65,370 52,423 12,947 Loss from operations(65,370)(52,423)(12,947)Other income:Interest income10,123 6,051 4,072 Other income419 532 (113)Total other income:10,542 6,583 3,959 Net loss$(54,828)$(45,840)$(8,988)

21

 Research and Development Expenses

The following table summarizes our research and development expenses (in thousands):

Nine Months Ended September 30,Change20252024Direct research and development expenses by program:NBD1 and combination development programs(1)$25,540 $13,588 $11,952 Complementary modulator programs3,813 5,388 (1,575)Unallocated research and development expenses:IPR&D acquisition related costs— 13,639 (13,639)Personnel-related (including stock-based compensation)10,650 6,521 4,129 Other R&D related costs3,294 1,974 1,320 Facility, lab and depreciation1,798 1,925 (127)Total research and development expenses$45,095 $43,035 $2,060 

(1)NBD1 and combination development program costs include NBD1 stabilizer activities and development of our proprietary combination therapy. Complementary modulator program costs include manufacturing expenses for the complementary modulators.

Research and development expenses increased by $2.1 million to $45.1 million for the nine months ended September 30, 2025, from $43.0 million for the nine months ended September 30, 2024. The increase in research and development expenses was primarily due to:

•direct research and development expenses increased by $10.4 million primarily due to an increase in clinical programs and combination development activities; and

•unallocated research and development expenses decreased by $8.3 million primarily due IPR&D acquisition costs incurred in connection with our license agreement with AbbVie of $13.6 million in the third quarter of 2024, partially offset by a $4.1 million increase in personnel-related expenses including stock-based compensation, driven